Acumen Pharmaceuticals, Inc. (ABOS)
$
2.26
-0.29 (-12.83%)
Key metrics
Financial statements
Free cash flow per share
-1.9092
Market cap
136.9 Million
Price to sales ratio
0
Debt to equity
0.4446
Current ratio
4.0741
Income quality
0.9522
Average inventory
0
ROE
-1.1127
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, has a weighted average number of shares outstanding at 60,561,836.00 highlighting the company's shareholder base. The company reported a net loss of -$121,335,000.00 indicating challenges in its operations as it navigates the complexities of drug development. The gross profit ratio stands at 0.00 reflecting the efficiency of the company's production and sales operations, despite the inherent risks in the biopharmaceutical landscape. Additionally, Acumen incurred an interest expense of $4,224,000.00 which underscores its debt servicing obligations while pursuing innovation in therapeutic solutions. The company achieved a revenue of $0.00 indicating its niche market focus and commitment to addressing unmet needs in the treatment of Alzheimer's disease through its targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody currently in Phase I clinical trials targeting soluble amyloid-beta oligomers. In the financial market, the stock is affordable at $1.26 making it suitable for budget-conscious investors seeking entry points into emerging biopharmaceutical opportunities. However, the stock has a low average trading volume of 819,144.00 indicating lower market activity that may influence liquidity for potential investors. With a market capitalization of $136,895,884.00 the company is classified as a small-cap player, which often involves higher volatility but also the potential for substantial growth. Acumen Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and advancing the development of new therapies. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it undertakes its mission to enhance the lives of individuals affected by Alzheimer's disease through its promising research and development initiatives.
Is Acumen Pharmaceuticals, Inc. (ABOS) a good investment?
Investing in Acumen Pharmaceuticals, Inc. (ABOS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Acumen Pharmaceuticals, Inc. (ABOS)'s stock forecast?
Analysts predict Acumen Pharmaceuticals, Inc. stock to fluctuate between $0.86 (low) and $3.60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Acumen Pharmaceuticals, Inc.'s market capitalization?
As of 2026-03-30, Acumen Pharmaceuticals, Inc.'s market cap is $136,895,884, based on 60,573,400 outstanding shares.
How does Acumen Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Acumen Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Acumen Pharmaceuticals, Inc. (ABOS) stock?
To buy Acumen Pharmaceuticals, Inc. (ABOS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABOS. Place an order (Market, Limit, etc.).
What is the best time to invest in Acumen Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Acumen Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2 | Growth: 16.96%.
Where can I find Acumen Pharmaceuticals, Inc.'s investor relations reports?
Visit https://acumenpharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Acumen Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Acumen Pharmaceuticals, Inc. stock?
All-time high: $19.46 (2021-08-30) | All-time low: $0.86 (2025-04-21).
What are the key trends affecting Acumen Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
globenewswire.com
NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of its common stock at a price of $3.30 per share. Acumen expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses.
seekingalpha.com
Acumen Pharmaceuticals, Inc. ( ABOS ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Alex Braun - VP & Head of Investor Relations Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and welcome to the Acumen Pharma Third Quarter 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this call may be recorded.
seekingalpha.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Business Officer James Doherty - President & Chief Development Officer Presentation Unknown Analyst All right. Here we go.
seekingalpha.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Securities, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Pete George Stavropoulos - Cantor Fitzgerald & Co., Research Division Trung Chuong Huynh - UBS Investment Bank, Research Division Operator Good day, and welcome to the Acumen Pharmaceuticals Second Quarter 2025 Conference Call and Webcast.
globenewswire.com
NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2025 and provided a business update.
globenewswire.com
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
See all news
